BNP Paribas Financial Markets
NNNN

BNP Paribas Financial Markets’s Anbio Biotechnology NNNN Stock Holding History

BNP Paribas Financial Markets’s Portfolio NNNN Stock Details NNNN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Buy
11,800
+1,400
+13% +$35.1K ﹤0.01% 4327
2026
Q1 		$267K Buy
10,400
+9,400
+940% +$245K ﹤0.01% 3917
2025
Q4 		$30.1K Sell
1,000
-1,419
-59% -$39K ﹤0.01% 4907
2025
Q3 		$90.1K Buy
2,419
+1,158
+92% +$52K ﹤0.01% 4341
2025
Q2 		$39.9K Buy
+1,261
New +$12.1K ﹤0.01% 4342

Other funds holding NNNN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BFS
Bare Financial Services Gap, Pennsylvania $436M AUM 20.22% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.81B AUM 32.31% 1-Year Est. Return

BNP Paribas Financial Markets's NNNN Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Anbio Biotechnology (NNNN) stake by 13% in Q2 2026, buying an estimated $35.1K and bringing the position to 11,800 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #4327.

BNP Paribas Financial Markets first reported a position in NNNN in Q2 2025 and has held it in 5 quarters since. The position peaked at $267K in Q1 2026. 12 funds tracked by Wall St. Rank hold NNNN as of Q2 2026.

  • BNP Paribas Financial Markets held 11,800 shares of Anbio Biotechnology worth $162K as of Q2 2026.
  • BNP Paribas Financial Markets bought 1,400 Anbio Biotechnology shares in Q2 2026, an estimated $35.1K.
  • Anbio Biotechnology made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4327 holding.
  • BNP Paribas Financial Markets first reported a position in Anbio Biotechnology in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Financial Markets's Anbio Biotechnology position peaked at $267K in Q1 2026.
  • 12 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.